• 1
    Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: 31S8S.
  • 2
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 188899.
  • 3
    IMS Heath. National Prescription Audit PlusTM. London: IMS Health Inc., 2004 (January 2004–December 2004).
  • 4
    Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93: 203746.
    Direct Link:
  • 5
    Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J 2005; 331: 13106.
  • 6
    Bombardier C, Laine L, Reicin A, et al. , VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 7
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 124755.
  • 8
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 2419.
  • 9
    Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 96773.
  • 10
    Pham K, Hirschberg R. Global safety of coxibs and NSAIDs. Curr Top Med Chem 2005; 5: 46573.
  • 11
    Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 13240.
  • 12
    Davenport HW. Gastric mucosal injury by fatty and acetyl salicylic acid. Gastroenterology 1964; 46: 24553.
  • 13
    Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury: topical injury revisited. Biochem Pharmacol 2001; 61: 6317.
  • 14
    Kao Y-CJ, Goddard PJ, Lichtenberger LM. Morphological effects of aspirin and prostaglandin on the canine gastric mucosal surface: analysis with a phospholipid cytochemical stain. Gastroenterology 1990; 98: 592606.
  • 15
    Lichtenberger LM, Wang ZM, Romero JJ, et al. NSAIDs associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced GI injury. Nat Med 1995; 1: 1548.
  • 16
    Giraud MN, Motta C, Romero JJ, Bommelaer G, Lichtenberger LM. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of non-steroidal anti-inflammatory drugs (NSAIDs). Biochem Pharmacol 1999; 57: 24754.
  • 17
    Anand BS, Romero JJ, Sanduja SK, et al. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 1999; 94: 181822.
    Direct Link:
  • 18
    Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury: effect of scoring method. Dig Dis Sci 1990; 35: 14949.
  • 19
    Greenwald DA. Aging, the gastrointestinal tract, and risk of acid-related disease. Am J Med 2004; 117(Suppl. 5A): 8S13S.
  • 20
    Pilotto A. Aging and upper gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004; 18: 7381.
  • 21
    Lanza FL, Rack MF, Simon TJ, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999; 13: 7617.
  • 22
    Chang DM, Young TH, Hsu CT, Kuo SY, Hsieh TC. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin Rheumatol 2001; 20: 10413.
  • 23
    Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591602.
  • 24
    Graham DY. NSAID ulcers; prevalence and prevention. Mod Rheumatol 2000; 10: 27.
  • 25
    Hackelsberger A, Platzer U, Nilius M, et al. Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently. Gut 1998; 43: 4659.